Company intelligence / Profile preview
MatriSys Bioscience
- Ownership
- Private
- Development stage
- Phase 1
Overview
MatriSys’ lead candidate, a topical formulation of stabilized lyophilized Staphylococcus hominis strain A9 (MSB‑01/MSB‑0221), has completed a successful Phase 1 trial in adults with atopic dermatitis showing safety and significant reduction of S. aureus colonization. The company is planning or conducting a randomized double-blind placebo-controlled Phase 2 trial for atopic dermatitis. Other pipeline programs are in earlier clinical or preclinical stages targeting additional dermatological indications[6].
- Therapeutic areas
- Dermatology
- Modalities
- Live biotherapeutic products (LBPs)Biological productsSmall molecule drugs[5]
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on MatriSys Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MatriSys Bioscience.